Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 341

1.

Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting.

Yaldo AZ, Wertz DA, Rupnow MF, Quimbo RM.

Clin Ther. 2008 Dec;30(12):2452-60. doi: 10.1016/j.clinthera.2008.12.010.

PMID:
19167603
2.

Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost.

Silberstein SD, Feliu AL, Rupnow MF, Blount AC, Boccuzzi SJ.

Headache. 2007 Apr;47(4):500-10.

PMID:
17445099
3.

Resource utilization impact of topiramate for migraine prevention in the managed-care setting.

Wertz DA, Quimbo RM, Yaldo AZ, Rupnow MF.

Curr Med Res Opin. 2009 Feb;25(2):499-503. doi: 10.1185/03007990802664199 .

PMID:
19192995
4.

Incidence and determinants of migraine prophylactic medication in the Netherlands.

Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts AC.

Eur J Clin Pharmacol. 2002 May;58(2):149-55. Epub 2002 Apr 5.

PMID:
12012149
5.

Topiramate prescribing patterns among medicaid patients: diagnosis, comorbidities, and dosing.

Poston S, Dickson M, Johnsrud M, Rupnow MF, Gdovin JM, Bramley TJ, Armstrong RB.

Clin Ther. 2007 Mar;29(3):504-18.

PMID:
17577471
6.

Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.

Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, Biondi D, Greenberg SJ, Hulihan J; CAPSS-277 Investigator Group.

Clin Ther. 2009 Mar;31(3):542-59. doi: 10.1016/j.clinthera.2009.03.020.

PMID:
19393844
7.

Resource use associated with topiramate in migraine prophylaxis.

Feliu AL, Rupnow MF, Blount A, Boccuzzi SJ, Vermilyea J.

Am J Health Syst Pharm. 2007 Jul 15;64(14):1483-91.

PMID:
17617498
8.

[Determinants of prophylactic migraine therapy in Spain].

Pascual-Gómez J, Caminero AB, Cano A, Heras-Pérez JA, Leira-Muiño R, García-Ribas G; grupo de investigadores participantes en el estudio PREVENTIA.

Rev Neurol. 2007 Nov 1-15;45(9):513-8. Spanish.

9.

Health care resource utilization following initiation of a triptan: a retrospective claims analysis.

Messali A, Owens G, Bloudek L, Kori S, Cole A, Chia J.

J Manag Care Spec Pharm. 2014 Apr;20(4):368-75.

10.
11.
12.

A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine.

Keskinbora K, Aydinli I.

Clin Neurol Neurosurg. 2008 Dec;110(10):979-84. doi: 10.1016/j.clineuro.2008.05.025. Epub 2008 Jul 11.

PMID:
18620801
13.

Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study.

Krymchantowski AV, Jevoux CC.

Headache. 2011 Apr;51(4):554-8. doi: 10.1111/j.1526-4610.2011.01868.x.

PMID:
21457240
14.

Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis.

He A, Song D, Zhang L, Li C.

J Headache Pain. 2017 Dec;18(1):26. doi: 10.1186/s10194-017-0720-7. Epub 2017 Feb 20.

15.

Prophylactic treatment of pediatric migraine.

Lewis DW, Diamond S, Scott D, Jones V.

Headache. 2004 Mar;44(3):230-7.

PMID:
15012660
16.

The effect of migraine prophylaxis on migraine-related resource use and productivity.

Láinez MJ.

CNS Drugs. 2009 Sep;23(9):727-38. doi: 10.2165/11314380-000000000-00000. Review.

PMID:
19689164
17.

Predictors of a negative response to topiramate therapy in patients with chronic migraine.

Rothrock JF, Parada VA, Drinkard R, Zweifler RM, Key KF.

Headache. 2005 Jul-Aug;45(7):932-5.

PMID:
15985112
18.

Migraine Prophylaxis and Acute Treatment Patterns Among Commercially Insured Patients in the United States.

Woolley JM, Bonafede MM, Maiese BA, Lenz RA.

Headache. 2017 Oct;57(9):1399-1408. doi: 10.1111/head.13157. Epub 2017 Aug 26.

PMID:
28842990
19.

Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.

Runken MC, Goodwin B, Shah M, Eaddy M, D'Souza A, Bowers B, Bell CF.

Appl Health Econ Health Policy. 2015 Feb;13(1):109-20. doi: 10.1007/s40258-014-0129-2.

PMID:
25294555
20.

Antiepileptic drugs in migraine prevention.

Mathew NT.

Headache. 2001 Nov-Dec;41 Suppl 1:S18-24. Review.

PMID:
11903536

Supplemental Content

Support Center